
Eledon Pharmaceuticals, Inc.: financial statements
Price
$1.78
November 20, 2026Market cap $204M
What Ploutos Investor adds for Eledon Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 14 fiscal years, from 2012
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 25% since Nov 12, 2026, when the 10-Q these figures come from was filed ($2.37 then, $1.78 on Nov 20, 2026). The figures date from before that move.10-Q
Financial statements
Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.
Click a line to see it on the chart.
Operating income
| Line | 2023 | 2024 | 2025 | Average a year |
|---|---|---|---|---|
| Operating income | -$43M | -$36M | -$46M | |
| Net income | -$117M | -$36M | -$46M | |
| Earnings per share | -$4.73 | -$0.66 | -$0.52 | |
| Earnings per share, basic | -$4.73 | -$0.66 | -$0.52 |
Financial statements
ELDN's revenue, profits and cash flows from 2012 to 2022, 11 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.
In some years the company reports no operating income, so we show pre-tax income.
Debt and obligations
What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.
Leases
Dec 31, 2025Operating leases
$641.0K
Finance leases
–
- Average discount rate
- 9.4%
- Lease cost for the year
- $394.0K
The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing
Operating lease payments by year
Lease liability by year
Leases
ELDN's leases from 2019 to 2021, 2 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
From the statutory to the effective tax rate, 2025
Dec 31, 2025Statutory rate
21.0%
Effective rate
-0.1%
The company paid -0.1% in tax on its profit, 21.1 points below the US federal rate (21.0%). Below, the reasons it gives.
Statutory rate
21.0%
Fair-value remeasurements
+15.4 pts
Tax credits
+7.7 pts
Change in valuation allowance
-32.4 pts
Share-based compensation
-7.8 pts
Uncertain tax positions
-3.9 pts
State and local taxes
-0.1 pts
Difference the filing does not itemize
-0.1 pts
Effective rate
-0.1%
One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing
Effective tax rate by year
In a year of a loss or of very small profits the rate comes out negative or very large and says little. Those years are in grey.
Effective tax rate by year
The tax rate ELDN paid on its profit, from 2012 to 2022, 7 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Earnings quality
How the reported earnings were made, read from the filings. A description, not a score: our tests found no link between these measures and later share returns.
Taxes: deferred and paid
The deferred part was 14.3% of the tax charge in the year to Dec 31, 2025. The rows show the last 2 years.
Cash taxes paid were 93.3% of the current tax charge in the year to Dec 31, 2025.
- Deferred share, year to Dec 31, 2025$5.0K of $35.0K
- 14.3%
- Deferred share, year to Dec 31, 2024$431.0K of $431.0K
- 100.0%
- $28.0K paid, $30.0K current
- 93.3%
When profit in the accounts runs ahead of taxable profit, the deferred part grows. It also moves for reasons unrelated to how earnings are booked: tax-law changes, the use of past losses, and the US rule since 2022 that spreads research costs over five years. Where the notes report it, the tax-rate bridge under Debt and obligations shows how the rate gets from the statutory one to the effective one.
The earnings per share split is not shown: the latest figures are more than 18 months old.
Receivables and inventory against sales are not shown: a figure it needs is missing from the company's structured filings.
The allowance for doubtful accounts is not shown: the company does not tag it in its structured filings.
A reading is called out when it is above the 90th percentile of the same reading across the S&P 500, or, for a fall, below the 10th, as measured on 9 November 2026. Each part uses only the company's own filings.
The metrics a company reports about itself (users, stores, subscribers) are read for S&P 500 companies only.
The full analysis
What do Eledon Pharmaceuticals's filings show?
These are Eledon Pharmaceuticals's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
How much debt does ELDN have?
On December 31, 2025 Eledon Pharmaceuticals had total assets of $169M, debt of – and shareholders' equity of $81M.
Where are the figures from?
From Eledon Pharmaceuticals, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.